Modulation of the PI3K/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity
Discover Oncology · 05.05.2025 · 16 (1)
DOI: 10.1007/s12672-025-02471-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Discover Oncology, online erschienen am 05.05.2025. Verfasst von Neda Hedayati und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 212 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a critical intracellular signaling pathway that is pivotal in various cellular functions. It is in senescence, survival, and growth under normal physiological and pathological conditions, including neoplasms. Additionally, this pathway has been recognized as essential for the regulation of the cell cycle. Several previous studies have indicated that the PI3K/Akt signaling pathway can be influenced by various natural products, with resveratrol (3,4',5-trihydroxy-trans-stilbene) being a particularly important phytoalexin polyphenol in this context. This review explores the impact of the PI3K/Akt signaling pathway on the initiation and advancement of various cancerous conditions and the potential of resveratrol to target this signaling mechanism. The review begins by summarizing the anti-tumor capabilities of resveratrol and then emphasizes the significant role of the PI3K/Akt signaling pathway in the progression of multiple malignancies. Finally, we discuss the therapeutic effects of resveratrol on human neoplasms, from brain cancers to gastrointestinal malignancies, through regulation of this signaling cascade.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Department of Internal Medicine, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
- Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
- Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran.
- Farhikhtegan Medical Convergent Sciences Research Center, TeMs. C., Islamic Azad University, Tehran, Iran.
- Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.
Zitieren
APA
Hedayati, N., Safari, M. H., Milasi, Y. E., Kahkesh, S., Farahani, N., Khoshnazar, S. M., Dorostgou, Z., Alaei, E., Alimohammadi, M., Rahimzadeh, P., Taheriazam, A., & Hashemi, M. (2025). Modulation of the PI3K/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity. Discover Oncology, 16(1). https://doi.org/10.1007/s12672-025-02471-w
Vancouver
Hedayati N, Safari MH, Milasi YE, Kahkesh S, Farahani N, Khoshnazar SM, et al. Modulation of the PI3K/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity. Discover Oncology. 2025;16(1). doi:10.1007/s12672-025-02471-w
BibTeX
@article{Hedayati2025,
author = {Hedayati, Neda and Safari, Mohamad Hosein and Milasi, Yaser Eshaghi and Kahkesh, Samaneh and Farahani, Najma and Khoshnazar, Seyedeh Mahdieh and Dorostgou, Zahra and Alaei, Elmira and Alimohammadi, Mina and Rahimzadeh, Payman and Taheriazam, Afshin and Hashemi, Mehrdad},
title = {Modulation of the PI3K/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity},
journal = {Discover Oncology},
year = {2025},
volume = {16},
number = {1},
doi = {10.1007/s12672-025-02471-w}
}
EUVIMED